Cargando…
Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration
High-throughput ?omics? technologies that generate molecular profiles for biospecimens have been extensively used in preclinical studies to reveal molecular subtypes and elucidate the biological mechanisms of disease, and in retrospective studies on clinical specimens to develop mathematical models...
Autores principales: | McShane, Lisa M, Cavenagh, Margaret M, Lively, Tracy G, Eberhard, David A, Bigbee, William L, Williams, P Mickey, Mesirov, Jill P, Polley, Mei-Yin C, Kim, Kelly Y, Tricoli, James V, Taylor, Jeremy MG, Shuman, Deborah J, Simon, Richard M, Doroshow, James H, Conley, Barbara A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3852338/ https://www.ncbi.nlm.nih.gov/pubmed/24228635 http://dx.doi.org/10.1186/1741-7015-11-220 |
Ejemplares similares
-
Criteria for the use of omics-based predictors in clinical
trials
por: McShane, Lisa M., et al.
Publicado: (2013) -
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): An
Abridged Explanation and Elaboration
por: Sauerbrei, Willi, et al.
Publicado: (2018) -
Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration
por: Altman, Douglas G, et al.
Publicado: (2012) -
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration
por: Altman, Douglas G., et al.
Publicado: (2012) -
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration
por: Vandenbroucke, Jan P, et al.
Publicado: (2007)